Comparative Study of Three NNRTI-Sparing HAART Regimens
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
The U.S. Department of Health and Human Services (HHS) guidelines recommend that HIV infected
patients who have never received anti-HIV therapy be treated with a triple drug regimen. The
most commonly prescribed and successful regimen contains the medication efavirenz (EFV).
However, this regimen may not be an option for everyone, hence alternative regimens are
needed.
This study was designed to look at how well different combinations of anti-HIV drugs work to
decrease the amount of HIV in the blood (viral load) of and allow immune system recovery in
people who have never received anti-HIV therapy. This study also examined drug tolerability
and safety for the various drug combinations.
Phase:
Phase 3
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborators:
Bristol-Myers Squibb Gilead Sciences Merck Sharp & Dohme Corp. National Institute of Allergy and Infectious Diseases (NIAID) Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA